Business context and reporting period
Tiziana Life Sciences Ltd, a foreign private issuer that files annual reports on Form 20-F, furnished this Form 6-K on September 28, 2026. The report announces progress in its clinical development program.
Key development
The first three participants received their first dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. The referenced September 28, 2026 press release is identified as Exhibit 99.1, but its text is not included in the supplied filing content.
Financial performance and changes
The supplied filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period financial results. It also provides no financial guidance or outlook.
Commentary, risks, and contingencies
No management commentary, trial results, safety findings, risks, or contingencies are described in the supplied text. The announcement reports dosing initiation for three participants, not clinical efficacy or safety outcomes.
The company states that the information and exhibit are furnished, not deemed filed for purposes of Exchange Act Section 18, and not incorporated by reference except as specifically stated.
Important facts for investors to verify
- Review Exhibit 99.1 for additional details about the trial, dosing, and next milestones.
- Verify the trial’s enrollment, design, timeline, and any subsequent safety or efficacy updates.
- Consult the company’s financial filings for current financial position, cash runway, and funding needs; these are not provided here.